IP Library Granted Patent US 9,877,981
Granted Patent B2
US 9,877,981 · App. 14/434,573 · Granted Jan 30, 2018

NAD biosynthesis and precursors for the treatment and prevention of cancer and proliferation

Inventors: David A. Sinclair (Chestnut Hill, MA); Ana P. Gomes (New York, NY); Lindsay Wu (Coogee, AU)
Assignees: President and Fellows of Harvard College; NewSouth Innovations Pty Limited
A61K31/7064A61K38/45A61K48/005A01K2217/075A01K2227/105A01K2267/035A61K31/706C12Y204/02012C12Y207/07001
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,877,981
App. No.
14/434,573
Granted
Jan 30, 2018
Kind
B2
Abstract

Disclosed herein are novel compositions and methods for the treatment of age-related diseases, mitochondrial diseases, the improvement of stress resistance, the improvement of resistance to hypoxia and the extension of life span. Also described herein are methods for the identification of agents useful in the foregoing methods. Methods and compositions are provided for the treatment of diseases or disorders associated with mitochondrial dysfunction. The invention relates to methods for treatment and prevention of cancer by administering agents that increase levels of NAD+, such as NAD+ precursors or agents involved in NAD+ biosynthesis.

Claims (19)

1. A method for treating or preventing cancer in a subject in need thereof comprising administering to the subject an amount of nicotinamide mononucleotide (NMN), or a salt thereof, or a prodrug thereof, effective to increase the level of nicotinamide adenine dinucleotide (NAD+) in the subject.

2. The method of claim 1 , wherein the NMN or salt thereof, or prodrug thereof, is administered at a dose of between 0.5-5 grams per day.

3. The method of claim 1 , wherein the subject is a human.

4. The method of claim 1 , wherein the NMN or salt thereof, or prodrug thereof, is administered as a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the NMN or salt thereof, or prodrug thereof.

5. The method of claim 4 , wherein the pharmaceutical composition is adapted for oral administration.

6. The method of claim 1 , wherein the NMN or salt thereof, or prodrug thereof, is administered orally.

7. The method of claim 2 , wherein the NMN or salt thereof, or prodrug thereof, is administered orally.

8. The method of claim 4 , wherein the NMN or salt thereof, or prodrug thereof, is administered orally.

9. The method of claim 2 , wherein the subject is a human.

10. The method of claim 4 , wherein the subject is a human.

11. The method of claim 5 , wherein the subject is a human.

12. The method of claim 2 , wherein the NMN or salt thereof, or prodrug thereof, is administered as a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the NMN or salt thereof, or prodrug thereof.

13. The method of claim 12 , wherein the pharmaceutical composition is adapted for oral administration.

14. The method of claim 12 , wherein the NMN or salt thereof, or prodrug thereof, is administered orally.

15. A method for treating or preventing cancer in a subject in need thereof, comprising administering to the subject an amount of NMN, or a salt thereof, effective to increase the level of NAD+ in the subject.

16. The method of claim 15 , wherein the NMN or salt thereof is administered at a dose of between 0.5-5 grams per day.

17. The method of claim 15 , wherein the NMN or salt thereof is administered as a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the NMN or salt thereof.

18. The method of claim 17 , wherein the pharmaceutical composition is adapted for oral administration.

19. The method of claim 17 , wherein the NMN or salt thereof is administered orally.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2016
From: WU, LINDSAY
To: NEWSOUTH INNOVATIONS PTY LIMITED
Reel/Frame 038925/0431 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2015
From: SINCLAIR, DAVID A.; GOMES, ANA P.
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 036223/0729 →
CONFIRMATORY LICENSE Recorded Apr 24, 2015
From: HARVARD UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035511/0277 →
Continuity (4)
Provisional Application 61711552 · Oct 9, 2012
Provisional Application 61832414 · Jun 7, 2013
Provisional Application 61832203 · Jun 7, 2013
Related Publication 20150313930A1 · Nov 5, 2015